|

Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project

RECRUITINGSponsored by CND Life Sciences
Actively Recruiting
SponsorCND Life Sciences
Started2023-11-30
Est. completion2026-02-28
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07005947

Summary

This is a prospective, longitudinal study involving 300 participants for a single visit to compare Long COVID-19 neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria, just one of the following:

* Long COVID-19 defined by NIH PASC criteria OR
* Acute COVID-19 who tested positive for COVID-19 without persistent symptoms OR
* Postural orthostatic tachycardia syndrome (POTS) OR
* Diabetic neuropathy

Exclusion Criteria:

* Clinical evidence of severe peripheral vascular disease
* History of ulceration, poor wound healing or vascular claudication
* History of allergic reaction to local anesthesia (for biopsy collection)
* Use of oral anticoagulants (aspirin or Plavix alone is allowed)
* History of a bleeding disorder

Conditions5

Acute COVID-19DiabetesDiabetic NeuropathyLong COVID-19Postural Orthostatic Tachycardia Syndrome (POTS)

Locations1 site

CND Life Sciences
Scottsdale, Arizona, 85258
Aracely Galarza480-847-0312agalarza@cndlifesciences.com

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.